HC Wainwright Estimates Geron’s Q3 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Equities researchers at HC Wainwright issued their Q3 2024 EPS estimates for Geron in a research note issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will earn ($0.09) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s FY2024 earnings at ($0.36) EPS and FY2025 earnings at ($0.23) EPS.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business’s revenue was up 2941.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) earnings per share.

Several other research firms have also recently weighed in on GERN. StockNews.com raised shares of Geron to a “sell” rating in a report on Monday, August 5th. Scotiabank started coverage on Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Geron in a research note on Thursday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Geron in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Geron presently has a consensus rating of “Moderate Buy” and an average price target of $7.05.

Geron Stock Down 0.7 %

GERN opened at $4.22 on Wednesday. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12. The firm has a 50 day moving average price of $4.33 and a 200-day moving average price of $4.30. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -11.72 and a beta of 0.52.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. National Bank of Canada FI grew its stake in shares of Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,000 shares during the period. Crewe Advisors LLC grew its stake in shares of Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 8,700 shares during the period. Kingsview Wealth Management LLC bought a new position in shares of Geron during the 1st quarter valued at approximately $34,000. American Trust bought a new position in shares of Geron during the 1st quarter valued at approximately $38,000. Finally, Rovin Capital UT ADV bought a new position in shares of Geron during the 3rd quarter valued at approximately $62,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.